All Oncology News

Breast cancer experts highlight early-phase and real-world studies of interest from the 2024 ESMO Congress.

Daratumumab-based induction/consolidation and maintenance therapy resulted in durable MRD negativity in patients with newly diagnosed multiple myeloma.

T-DXd shows substantial antitumor activity in brain metastases in patients with HER2-positive breast cancer in a major international clinical trial.

D-VRd induction and consolidation therapy displayed a PFS benefit vs VRd in high-risk subgroups of patients with newly diagnosed multiple myeloma.

Detalimogene voraplasmid generated a 71% complete response rate in patients with BCG-unresponsive non–muscle invasive bladder cancer and CIS.

The FDA’s ODAC voted against the risk:benefit profile of PD-1 inhibitors in first-line advanced gastric/GEJ adenocarcinoma with a PD-L1 of less than 1.

A supplemental new drug application seeking to expand the indication for darolutamide plus ADT in mHSPC has been submitted to the FDA.

Belantamab mafodotin-based combination appears to improve responses over time in those with transplant-eligible newly diagnosed multiple myeloma

The risk of lymphedema was comparable for hypofractionated radiation therapy and normofractionated radiation therapy in early breast cancer.

Oncology experts share their key takeaways in genitourinary cancers and recent updates from the 2024 ESMO Congress.

The FDA approved osimertinib for EGFR-mutated, locally advanced, unresectable, non–small cell lung cancer after chemoradiation.

Bora Lim, MD, discusses the significance of the FDA approval of adjuvant ribociclib for patients with HR-positive, HER2-negative breast cancer.

Treatment for blood cancers is advancing, giving more options to people living with the disease.

The European Commission has approved toripalimab in indications for nasopharyngeal carcinoma and esophageal squamous cell carcinoma.

The combination of favezelimab and pembrolizumab failed to improve OS vs regorafenib or TAS-102 in pretreated patients with PD-L1–positive, MSS mCRC.

The phase 3 KarMMa-9 trial of ide-cel plus lenalidomide maintenance in newly diagnosed multiple myeloma after ASCT has discontinued enrollment.

Read about the early-phase sarcoma studies presented at the 2024 ESMO Congress that experts are keeping their eyes on.

A statistically significant difference in PFS was not observed between chemotherapy backbone and HRD status in first-line TNBC.

Adjuvant pembrolizumab generated a DFS benefit vs observation in patients with high-risk muscle-invasive bladder cancer after radical surgery.

BL-B01D1 displayed safety and preliminary efficacy in previously treated locally advanced or metastatic urothelial carcinoma.

The FDA has granted fast track designation to EO-3021 for use in select patients with claudin 18.2–expressing gastric or GEJ cancer.

Black patients and older adults are least likely to undergo this treatment for blood cancers and hematologic disorders.

LODER plus chemotherapy led to responses and improved overall survival in unresectable, locally advanced pancreatic cancer.

Enfortumab vedotin plus pembrolizumab has been approved in Japan for first-line radically unresectable urothelial carcinoma.

Japan’s Ministry of Health, Labour, and Welfare approved fruquintinib in metastatic colorectal cancer following progression with chemotherapy.

Medicare drug price negotiations may impact community oncology practices, leading to potential changes in drug access, reimbursement, and patient care strategies.

Patients with HR-positive breast cancer who conceived during a break from endocrine therapy found breastfeeding feasible and safe.

The FDA has granted rare pediatric disease designation to LP-184 in malignant rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma.

The SOLARIS trial results suggest that high-dose vitamin D3 cannot be recommended as a treatment for patients with untreated metastatic colon cancer.

BDTX-1535 yielded durable clinical activity in patients with relapsed/refractory, EGFR-mutant NSCLC harboring resistance mutations.